Tirzepatide vs CagriSema: Next-Generation Weight Loss Peptide Comparison | Peptpedia
This comprehensive analysis compares Tirzepatide and CagriSema (Cagrilintide + Semaglutide) based on peer-reviewed clinical research, examining their mechanisms of action, efficacy data, and safety profiles. For complete individual peptide profiles, visit the dedicated research pages linked above.
Tirzepatide and CagriSema (cagrilintide + semaglutide) represent two distinct multi-receptor approaches to obesity pharmacotherapy. Tirzepatide's SURMOUNT-1 trial achieved 22.5% body weight loss at the highest dose; REDEFINE 1 demonstrated CagriSema achieving 20.4% weight loss. Both approaches demonstrate weight loss approaching the efficacy of bariatric surgery, but through different complementary receptor mechanisms.
Chemical Identity
Side-by-Side Comparison
| Property | Tirzepatide | CagriSema (Cagrilintide + Semaglutide) |
|---|---|---|
| Mechanism | Dual GIP + GLP-1 receptor agonist (single molecule) | GLP-1 + amylin receptor dual activation (combination) |
| Components | Tirzepatide (single peptide) | Semaglutide 2.4 mg + Cagrilintide 2.4 mg |
| Receptors Targeted | GIP-R + GLP-1R | GLP-1R + AMY receptors (AMY1-3, CTR) |
| Max Weight Loss | 22.5% (15 mg, SURMOUNT-1) | 20.4% (REDEFINE 1) |
| Approval Status | FDA approved (Zepbound) | Phase 3 (not yet approved) |
| Administration | Once-weekly subcutaneous | Once-weekly subcutaneous (two injections) |
Weight Loss Efficacy: Trial-by-Trial Comparison
Tirzepatide (SURMOUNT-1 trial, n=2,539): At 72 weeks, 5 mg achieved 15.0%, 10 mg achieved 19.5%, and 15 mg achieved 20.9% mean body weight reduction. A subsequent analysis with extended follow-up showed the 15 mg dose achieving 22.5%. This represented the highest weight loss efficacy of any approved pharmaceutical agent at the time of approval.
CagriSema (REDEFINE 1 trial, n=3,414): At 68 weeks, CagriSema 2.4/2.4 mg achieved 20.4% mean body weight reduction, with 40.4% of participants achieving >25% weight loss. This was significantly greater than the semaglutide 2.4 mg monotherapy control arm (~14.9%). The combination's unique feature is that the amylin pathway (cagrilintide) provides complementary satiety signaling to GLP-1 agonism.
Frequently Asked Questions
Research Citations
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). New England Journal of Medicine